

**Reva Pharmachem Private Limited****Part - I : Balance Sheet**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

Particulars	Note	As at	
		31.03.2022	31.03.2021
<b>ASSETS</b>			
<b>Non Current Assets</b>			
a) Financial Assets		-	-
		-	-
<b>Current Assets</b>			
a) Financial Assets			
i) Cash and Cash Equivalents	2	-	236
		-	<b>236</b>
<b>Total</b>		-	<b>236</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
a) Equity Share Capital	3	3,000	3,000
b) Other Equity	4	(3,006)	(2,838)
		<b>(6)</b>	<b>162</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
a) Financial Liabilities			
i) Trade Payables			
- total outstanding dues of creditors other than micro enterprises and small enterprises		-	-
b) Other Current Liabilities	5	-	8
c) Provisions	6	6	67
		<b>6</b>	<b>74</b>
<b>Total</b>		-	<b>236</b>

Notes form an Integral part of financial statements

As per our even report attached  
for Bohara Bhandari Bung And Associates LLP  
Chartered Accountants  
(Firm's Regn No.008127S/S-200013)

CA. Pankaj Kumar Bohara  
Partner  
M.No.215471

Place: Raichur  
Date: 20.04.2022



for and on behalf of Board of Directors

Gupreet Singh Sandhu  
Director  
DIN No. 02685996

Ramakant Innani  
Director  
DIN No. 03222748

Place: Raichur  
Date: 20.04.2022



**Reva Pharmachem Private Limited**

**Part - II - Statement of Profit and Loss**

(All amounts are in Indian Rupees in thousands except share data & per share data unless otherwise stated)

Particulars	Note	For the year ended 31.03.2022	For the year ended 31.03.2021
Revenue from Operations		-	-
Other Income	7	27	-
<b>Total Income</b>		<b>27</b>	<b>-</b>
<b>Expenses</b>			
a) Finance Costs		-	62
b) Other Expenses	8	194	817
<b>Total Expenses</b>		<b>194</b>	<b>879</b>
<b>Profit / (Loss) before exceptional items and tax</b>		<b>(168)</b>	<b>(879)</b>
Exceptional income/(expenses)		-	-
<b>Profit / (Loss) before tax</b>		<b>(168)</b>	<b>(879)</b>
<b>Tax Expense</b>			
a) Current Taxes		-	-
b) Taxes pertaining to earlier years		-	1
c) Deferred Taxes (Net)		-	-
Less: MAT Credit Entitlement		-	-
		-	<b>1</b>
<b>Profit / (Loss) for the year</b>		<b>(168)</b>	<b>(880)</b>
<b>Other Comprehensive Income</b>		<b>-</b>	<b>-</b>
<b>Total Comprehensive Income</b>		<b>(168)</b>	<b>(880)</b>
<b>Earning per equity share for Rs.10/- face value (Continued Operations)</b>			
Basic		(0.56)	(2.93)
Diluted		(0.56)	(2.93)
<b>Number of shares used in computing earnings per share (Continued Operations)</b>			
Basic		3,00,000	3,00,000
Diluted		3,00,000	3,00,000

Notes form an Integral part of financial statements  
As per our even report attached

for **Bohara Bhandari Bung And Associates LLP**  
**Chartered Accountants**  
(Firm's Regn No.008127S/S-200013)



**CA. Pankaj Kumar Bohara**  
**Partner**  
M.No.215471

Place: Raichur  
Date: 20.04.2022



for and on behalf of Board of Directors



**Gurpreet Singh Sandhu**  
**Director**  
DIN No. 02685996

Place: Raichur  
Date: 20.04.2022



**Ramakant Innani**  
**Director**  
DIN No. 03222748



## **NOTES TO THE FINANCIAL STATEMENTS**

### **CORPORATE INFORMATION**

Reva Pharmachem Private Limited (the Company) is a Private Limited Company incorporated on 23.11.2009 with its registered office at Raichur. Presently, the Company is engaged in the business of Retail Trading of Drugs and Pharmaceuticals.

#### **1. Basis of Preparation**

- i. These financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) as specified under section 133 of the Companies Act 2013 read together with the Rule 4 of Companies (Indian Accounting Standards) Rules, 2015 as amended by Companies (Indian Accounting Standards) Amendment Rules 2016 to the extent applicable and the other relevant provisions of the Act, pronouncements of the regulatory bodies applicable to the company.
- ii. The financial statements have been prepared on going concern and accrual basis. The accounting policies are applied consistently to all the periods presented in the financial statements.

The financial statements of the Company for the year ended March 31, 2022 were approved by the Board of Directors on 20/04/2022.

- iii. The financial statements have been prepared to comply in all material aspects with applicable accounting principal in India and as notified under the Companies Act, 2013 and the other relevant provisions of the Act.
- iv. The Ind AS Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities as specified and defined benefit plans which have been measured at actuarial valuation as required by relevant Ind AS.

#### **1.1 Significant Accounting Policies**

##### **a) Functional and Presentation currency:**

These financial statements are presented in Indian rupees ("INR") which is also the Company's functional currency. All amounts have been reported in Indian Rupees, except for share and per share data, unless otherwise stated. Due to rounding off, the numbers presented throughout the document may not add up precisely to the totals and percentages may not precisely reflect the absolute figures.

##### **b) Critical accounting Estimates and Judgements:**

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Revisions to accounting estimates are recognised prospectively.

previously recognised in OCI is reclassified from the equity to 'other income' in the Statement of Profit and Loss.

### **(c) Financial Assets at fair value through profit or loss (FVTPL)**

Financial Asset are measured at Fair value through Profit & Loss if it does not meet the criteria for classification as measured at amortized cost or at FVTOCI. All fair value changes are recognized in the statement of Profit & Loss.

### **Equity Instruments**

All investments in equity instruments classified under financial assets are initially measured at fair value, the group may, on initial recognition, irrevocably elect to measure the same either at FVOCI or FVTPL.

### **De-recognition of Financial Assets:**

Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire or the financial asset is transferred and the transfer qualifies for Derecognition. On Derecognition of a financial asset in its entirety, the difference between the carrying amount (measured on the date of recognition) and the consideration received (including any new asset obtained less any new liability assumed) shall be recognized in the statement of Profit & Loss.

### **Impairment of Financial Assets:**

In accordance with Ind AS 109, the company applies expected credit loss (ECL) model by adopting the simplified approach using a provision matrix reflecting current condition and forecasts of future economic conditions for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- (a) Financial Assets that are debt instruments, and are measured at amortized cost e.g. loans, debt securities, deposits, trade receivables and bank balance
- (b) Financial Assets that are debt instruments and are measured at FVTOCI.
- (c) Lease receivables under Ind AS 17.
- (d) Trade receivables or any contractual right to receive cash or another financial asset
- (e) Loan commitments which are not measured at FVTPL
- (f) Financial guarantee contracts which are not measured at FVTPL

## **(II) Financial Liability**

### **Initial recognition and measurement**

Financial liabilities are recognized initially at fair value plus any transaction cost that are attributable to the acquisition of the financial liability except financial liabilities at FVTPL that are measured at fair value.

### **Subsequent measurement**

reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. Contingent Liabilities are not recognized but are disclosed in the notes.

**f) Earnings per share**

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.

**g) Cash Flow Statements**

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

**h) Cash and Cash Equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand, short-term deposits and other short-term highly liquid investments with an original maturity of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

For the purposes of the presentation of cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft as they being considered as integral part of the Company's cash management system.

**i) Recent accounting pronouncements:**

MCA issued notifications dated March 23, 2022 to amend schedule III to the companies Act 2013, to enhance the disclosure required to be made by the company in its financial statements. These amendments are applicable to the Company for the financial year starting April 01, 2022. The amendments are extensive, and the Company will evaluate the same to give effect to them as required by law.

**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**STATEMENT OF CHANGES IN EQUITY for the year ended 31.03.2022**

**A. Equity Share Capital**

Particulars	Total
Balance as at 01 April, 2020	-
Changes in equity share capital during the year	-
Balance as at 31 March, 2021	-
Changes in equity share capital during the year	-
Balance as at 31 March, 2022	-

**B. Other Equity**

Particulars	Retained Earnings	As at 31.03.2022	As at 31.03.2021
Balance at the beginning of the reporting period	(2,838)	(2,838)	(1,958)
Changes during the period	-	-	-
Restated balance at the beginning of the reporting period	(2,838)	(2,838)	(1,958)
Changes during the period	-	-	-
Total Comprehensive Income for the Year	(168)	(168)	(880)
Balance at the end of the reporting period	(3,006)	(3,006)	(2,838)

**Notes:**

1. Retained Earnings: This reserve represents the cumulative losses of the company.



**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**9 Payments to the auditor**

<b>Particulars</b>	<b>31.03.2022</b>	<b>31.03.2021</b>
a) Statutory Audit	6	20
b) Other	24	29
<b>Total</b>	<b>30</b>	<b>49</b>

**10 Earnings per share (EPS)**

<b>Particulars</b>	<b>31.03.2022</b>	<b>31.03.2021</b>
Net profit after tax attributable to equity shares holders for Basic EPS	(168)	(880)
Weighted Average no of equity shares outstanding during the year for Basic & Diluted EPS	3,00,000	3,00,000
Basic & Diluted EPS	(0.56)	(2.93)
Nominal Value per share	10.00	10.00



**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**11 Related party transactions**

<u>Name of the Entity</u>	<u>Relationship</u>
Shilpa Medicare Limited	Associate Company
Akira Pharma Private Limited	Entity having common director (KMP)
Reva Medicare Private Limited	Entity having common director (KMP)
Gurpreet Singh Sandhu	Key Management Person

Sl. No.	Name of the person	Relationship	Description of transaction	April 01, 2021 to March 31, 2022 Income/ (Expense), Other Transaction	Balance as at March 31, 2022 (Payable) / Receivable	April 01, 2020 to March 31, 2021 Income/ (Expense), Other Transaction	Balance as at March 31, 2021 (Payable) / Receivable
1	Reva Medicare Pvt. Ltd.	Private limited company in which a Director is a Director	Expenses incurred by related party on behalf of Reva Pharma Support Service	(21)  (117)	-  -	(11)	-





**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**(i) Foreign Currency Risk**

The Company does not operate internationally in terms of revenues.

Note : No Foreign transactions during the period and hence disclosure of information not applicable.

**(ii) Interest Rate Risk**

Interest rate risk is the risk that the fair value of future cash flows of the financial instruments will fluctuate because of changes in market interest rates. The Company does not have any type of borrowings hence there is no interest rate risk.

**(iii) Price Risk**

The company does not have any exposure to price risk, as there is no market based equity investment made by the company.

**(B) Credit Risk**

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The credit risk is arises from its operation activity primarily from trade receivable and from its financial activity. Customer credit risk is controlled by analysis of credit limit and credit worthness of the customer on a continuous basis to whom the credit has been granted.

**(C) Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations of its financial liability. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for paying liability when they are due, under normal and stressed condition without incurring losses and risk.

The present available working capital facility is sufficient to meet its current requirement. Accordingly no liquidity risk is perceived. In addition, the Company maintains the following line of credit facility.

Note : No financial liabilities during the period and hence maturity table not provided

**13 Capital Management**

The Company's objectives when managing capital are to

- i) Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders.
- ii) Maintain an optimal capital structure to reduce the cost of capital.

Consistent with others in the industry, the Company monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings net of cash and cash equivalents) divided by total 'equity' (as shown in the balance sheet)

Note: Company doesn't have borrowings and hence debt equity ratio not provided in table.

**14 Income Tax**

**Reconciliation of tax expenses and the accounting profit multiplied by Tax Rate**

Note : Tax expenses/income not there in current as well previous year, hence Tax reconciliation and deferred tax movement not given.



**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**24 Compliance with number of layers of companies**

The Company has complied with the number of layers prescribed under the Section 2 (87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rule, 2017.

**25 Utilisation of borrowed funds and share premium**

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entities ("Intermediaries") with the understanding whether recorded in writing or otherwise, that the intermediary shall lend or invest in party identified by or on behalf of the company (Ultimate Beneficiaries). The Company has not received any fund from any party (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries. The Company has complied with the number of layers prescribed under the Section 2 (87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rule, 2017.

**26 Undisclosed Income**

There is not income surrendered or disclosed as income during the current or previous year in the tax assessments under the income tax act, 1961, that has not been recorded previously in the books of account.

**27 Details of crypto currency or virtual currency**

The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

**28 Utilisation of borrowings availed from banks and financial institutions**

The company has not obtained borrowings from banks and financial institutions.

**29 Previous year figures have been regrouped / reclassified wherever necessary to confirm current year classification.**

As per report of even date attached  
for Bohara Bhandari Bung And Associates LLP  
Chartered Accountants  
(Firm's Regn No.008127S/S-200013)

  
CA. Pankaj Kumar Bohara  
Partner  
M.No.215471

Place: Raichur  
Date: 20.04.2022



for and on behalf of Board of Directors of Reva  
Pharmachem Private Limited

  
Gulpreet Singh Sandhu  
Director  
DIN No. 02685996

Place: Raichur  
Date: 20.04.2022

  
Ramakant Innani  
Director  
DIN No. 03222748



**Reva Pharmachem Private Limited****Part - I : Balance Sheet**

(All amounts are in Indian Rupees unless otherwise stated)

Particulars	Note	As at	
		31.03.2022	31.03.2021
<b>ASSETS</b>			
<b>Non Current Assets</b>			
a) Financial Assets		-	-
<b>Current Assets</b>			
a) Financial Assets			
i) Cash and Cash Equivalents	2	-	2,36,046
<b>Total</b>		-	<b>2,36,046</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
a) Equity Share Capital	3	30,00,000	30,00,000
b) Other Equity	4	(30,06,000)	(28,38,404)
		<b>(6,000)</b>	<b>1,61,596</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
a) Financial Liabilities			
i) Trade Payables			
- total outstanding dues of creditors other than micro enterprises and small enterprises		-	-
b) Other Current Liabilities	5	-	7,875
c) Provisions	6	6,000	66,575
		<b>6,000</b>	<b>74,450</b>
<b>Total</b>		-	<b>2,36,046</b>

Notes form an Integral part of financial statements

As per our even report attached

for Bohara Bhandari Bung And Associates LLP

Chartered Accountants

(Firm's Regn No.008127S/S-200013)

CA. Pankaj Kumar Bohara

Partner

M.No.215471

Place: Raichur

Date: 20.04.2022



for and on behalf of Board of Directors

*Gurpreet Singh Sandhu*  
Gurpreet Singh Sandhu  
Director  
DIN No. 02685996

Place: Raichur  
Date: 20.04.2022

*Ramakant Innani*  
Ramakant Innani  
Director  
DIN No. 03222748



**Reva Pharmachem Private Limited**

**Cash Flow Statement for the year ended**

(All amounts are in Indian Rupees unless otherwise stated)

Particulars	31.03.2022	31.03.2021
<b>Cash Flows from Operating Activities</b>		
Profit / (Loss) Before Tax	(1,67,596)	(8,78,799)
<b>Add: Adjustments for:</b>		
Interest paid	-	61,977
Operating profit before working capital changes & Other Adjustments	<b>(1,67,596)</b>	<b>(8,16,822)</b>
<b>Adjustments for Increase / (Decrease) in Operating Liabilities</b>		
- Trade Payables	-	(90,975)
- Other Current Liabilities & Short Tem Provisions	(68,450)	(53,108)
<b>Adjustments for (Increase) / Decrease in Operating Receivables</b>		
- Trade Receivables	-	-
- Other Financial Assets	-	6,81,600
- Other Current Assets	-	4,31,662
	(2,36,046)	1,52,357
<b>Less:</b>		
Income Tax paid	-	3,86,623
<b>Net Cash flow from Operating activities</b>	<b>(2,36,046)</b>	<b>(2,34,266)</b>
<b>Cash Flows from Investing Activities</b>		
Written off of NSC	-	5,000
<b>Net cash used in Investing Activities</b>	<b>-</b>	<b>5,000</b>
<b>Cash Flows from Financing Activities</b>		
Interest paid	-	(61,977)
<b>Net Cash earned from Financing Activities</b>	<b>-</b>	<b>(61,977)</b>
<b>Net Increase/(decrease)in Cash and Cash Equivelants</b>	<b>(2,36,046)</b>	<b>(2,91,243)</b>
Cash & Cash Equivelants at the beginning of the year	2,36,046	5,27,289
<b>Cash &amp; Cash Equivelants at the end of the year</b>	<b>-</b>	<b>2,36,046</b>

Components of Cash and Cash Equivalents	31.03.2022	31.03.2021
Cash on Hand	-	838
Cash at Banks		
a) In Current Account	-	2,35,208
<b>Total Cash and Cash Equivalents</b>	<b>-</b>	<b>2,36,046</b>

**Note:**

- 1.Previous year figures have been reclassified wherever necessary.
2. Cash Flow statement has been prepared under Indirect method as per Ind AS-7 "Statement of Cash Flows"

As per our report of even date attached

for Bohara Bhandari Bung And Associates LLP  
Chartered Accountants  
(Firm's Regn No.008127S/S-200013)

CA. Pankaj Kumar Bohara  
Partner  
M.No.215471

Place: Raichur  
Date: 20.04.2022



for and on behalf of Board of Directors of Reva  
Pharmachem Private Limited

Gurpreet Singh Sandhu  
Director  
DIN No. 02685996

Place: Raichur  
Date: 20.04.2022

Ramakant Innani  
Director  
DIN No. 03222748



## NOTES TO THE FINANCIAL STATEMENTS

### CORPORATE INFORMATION

Reva Pharmachem Private Limited (the Company) is a Private Limited Company incorporated on 23.11.2009 with its registered office at Raichur. Presently, the Company is engaged in the business of Retail Trading of Drugs and Pharmaceuticals.

#### **1. Basis of Preparation**

i. These financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) as specified under section 133 of the Companies Act 2013 read together with the Rule 4 of Companies (Indian Accounting Standards) Rules, 2015 as amended by Companies (Indian Accounting Standards) Amendment Rules 2016 to the extent applicable and the other relevant provisions of the Act, pronouncements of the regulatory bodies applicable to the company.

ii. The financial statements have been prepared on going concern and accrual basis. The accounting policies are applied consistently to all the periods presented in the financial statements.

The financial statements of the Company for the year ended March 31, 2022 were approved by the Board of Directors on 20/04/2022.

iii. The financial statements have been prepared to comply in all material aspects with applicable accounting principal in India and as notified under the Companies Act, 2013 and the other relevant provisions of the Act.

iv. The Ind AS Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities as specified and defined benefit plans which have been measured at actuarial valuation as required by relevant Ind AS.

#### **1.1 Significant Accounting Policies**

##### **a) Functional and Presentation currency:**

These financial statements are presented in Indian rupees ("INR") which is also the Company's functional currency. All amounts have been reported in Indian Rupees, except for share and per share data, unless otherwise stated. Due to rounding off, the numbers presented throughout the document may not add up precisely to the totals and percentages may not precisely reflect the absolute figures.

##### **b) Critical accounting Estimates and Judgements:**

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Revisions to accounting estimates are recognised prospectively.



previously recognised in OCI is reclassified from the equity to 'other income' in the Statement of Profit and Loss.

**(c) Financial Assets at fair value through profit or loss (FVTPL)**

Financial Asset are measured at Fair value through Profit & Loss if it does not meet the criteria for classification as measured at amortized cost or at FVTOCI. All fair value changes are recognized in the statement of Profit & Loss.

**Equity Instruments**

All investments in equity instruments classified under financial assets are initially measured at fair value, the group may, on initial recognition, irrevocably elect to measure the same either at FVOCI or FVTPL.

**De-recognition of Financial Assets:**

Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire or the financial asset is transferred and the transfer qualifies for Derecognition. On Derecognition of a financial asset in its entirety, the difference between the carrying amount (measured on the date of recognition) and the consideration received (including any new asset obtained less any new liability assumed) shall be recognized in the statement of Profit & Loss.

**Impairment of Financial Assets:**

In accordance with Ind AS 109, the company applies expected credit loss (ECL) model by adopting the simplified approach using a provision matrix reflecting current condition and forecasts of future economic conditions for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- (a) Financial Assets that are debt instruments, and are measured at amortized cost e.g. loans, debt securities, deposits, trade receivables and bank balance
- (b) Financial Assets that are debt instruments and are measured at FVTOCI.
- (c) Lease receivables under Ind AS 17.
- (d) Trade receivables or any contractual right to receive cash or another financial asset
- (e) Loan commitments which are not measured at FVTPL
- (f) Financial guarantee contracts which are not measured at FVTPL

**(II) Financial Liability**

**Initial recognition and measurement**

Financial liabilities are recognized initially at fair value plus any transaction cost that are attributable to the acquisition of the financial liability except financial liabilities at FVTPL that are measured at fair value.

**Subsequent measurement**



reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. Contingent Liabilities are not recognized but are disclosed in the notes.

**f) Earnings per share**

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.

**g) Cash Flow Statements**

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

**h) Cash and Cash Equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand, short-term deposits and other short-term highly liquid investments with an original maturity of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

For the purposes of the presentation of cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft as they being considered as integral part of the Company's cash management system.

**i) Recent accounting pronouncements:**

MCA issued notifications dated March 23, 2022 to amend schedule III to the companies Act 2013, to enhance the disclosure required to be made by the company in its financial statements. These amendments are applicable to the Company for the financial year starting April 01, 2022. The amendments are extensive, and the Company will evaluate the same to give effect to them as required by law.



**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees unless otherwise stated)

**9 Payments to the auditor**

<b>Particulars</b>	<b>31.03.2022</b>	<b>31.03.2021</b>
a) Statutory Audit	6,000	20,000
b) Other	23,875	29,000
<b>Total</b>	<b>29,875</b>	<b>49,000</b>

**10 Earnings per share (EPS)**

<b>Particulars</b>	<b>31.03.2022</b>	<b>31.03.2021</b>
Net profit after tax attributable to equity shares holders for Basic EPS	(1,67,596)	(8,80,114)
Weighted Average no of equity shares outstanding during the year for Basic & Diluted EPS	3,00,000	3,00,000
Basic & Diluted EPS	(0.56)	(2.93)
Nominal Value per share	10.00	10.00





**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees unless otherwise stated)

**11 Related party transactions**

<b>Name of the Entity</b>	<b>Relationship</b>
Shilpa Medicare Limited	Associate Company
Akira Pharma Private Limited	Entity having common director (KMP)
Reva Medicare Private Limited	Entity having common director (KMP)
Gurpreet Singh Sandhu	Key Management Person

Sl. No.	Name of the person	Relationship	Description of transaction	April 01, 2021 to March 31, 2022 Income/ (Expense), Other Transaction	Balance as at March 31, 2022 (Payable) / Receivable	April 01, 2020 to March 31, 2021 Income/ (Expense), Other Transaction	Balance as at March 31, 2021 (Payable) / Receivable
I	Reva Medicare Pvt. Ltd.	Private limited company in which a Director is a Director	Expenses incurred by related party on behalf of Reva Pharma Support Service	(20,836) (1,17,362)	-	(11,126)	-



## Reva Pharmachem Private Limited

(All amounts are in Indian Rupees in thousands unless otherwise stated)

### (i) Foreign Currency Risk

The Company does not operate Internationally in terms of revenues.

Note : No Foreign transactions during the period and hence disclosure of information not applicable.

### (ii) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of the financial instruments will fluctuate because of changes in market interest rates. The Company does not have any type of borrowings hence there is no interest rate risk.

### (iii) Price Risk

The company does not have any exposure to price risk, as there is no market based equity investment made by the company.

### (B) Credit Risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The credit risk is arises from its operation activity primarily from trade receivable and from its financial activity. Customer credit risk is controlled by analysis of credit limit and credit worthness of the customer on a continuous basis to whom the credit has been granted.

### (C)Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations of its financial liability. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for paying liability when they are due, under normal and stressed condition without incurring losses and risk.

The present available working capital facility is sufficient to meet its current requirement. Accordingly no liquidity risk is perceived. In addition, the Company maintains the following line of credit facility,

Note : No financials liabilities during the period and hence maturity table not provided

## 13 Capital Management

The Company's objectives when managing capital are to

- i) Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders.
- ii) Maintain an optimal capital structure to reduce the cost of capital.

Consistent with others in the industry, the Company monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings net of cash and cash equivalents) divided by total 'equity' (as shown in the balance sheet)

Note: Company doesn't have borrowings and hence debt equity ratio not provided in table.

## 14 Income Tax

### Reconciliation of tax expenses and the accounting profit multiplied by Tax Rate

Note : Tax expenses/income not there in current as well previous year, hence Tax reconciliation and deferred tax movement not given.



**Reva Pharmachem Private Limited**

(All amounts are in Indian Rupees in thousands unless otherwise stated)

**24 Compliance with number of layers of companies**

The Company has complied with the number of layers prescribed under the Section 2 (87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rule, 2017.

**25 Utilisation of borrowed funds and share premium**

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entities ("Intermediaries") with the understanding whether recorded in writing or otherwise, that the intermediary shall lend or invest in party identified by or on behalf of the company (Ultimate Beneficiaries). The Company has not received any fund from any party (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries. The Company has complied with the number of layers prescribed under the Section 2 (87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rule, 2017.

**26 Undisclosed Income**

There is not income surrendered or disclosed as income during the current or previous year in the tax assessments under the income tax act, 1961, that has not been recorded previously in the books of account.

**27 Details of crypto currency or virtual currency**

The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

**28 Utilisation of borrowings availed from banks and financial institutions**

The company has not obtained borrowings from banks and financial institutions.

**29 Previous year figures have been regrouped / reclassified wherever necessary to confirm current year classification.**

As per report of even date attached  
for Bohara Bhandari Bung And Associates LLP  
Chartered Accountants  
(Firm's Regn No.008127S/S-200013)

  
CA. Pankaj Kumar Bohara  
Partner  
M.No.215471

Place: Raichur  
Date: 20.04.2022



for and on behalf of Board of Directors of Reva  
Pharmachem Private Limited

  
Gurpreet Singh Sandhu  
Director  
DIN No. 02685996

  
Ramakant Inani  
Director  
DIN No. 03222748

Place: Raichur  
Date: 20.04.2022

